Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:25 2024-09-17 EDT			5-day change	1st Jan Change
98.03 ^CHF	-0.39%		-0.79%	+15.51%

07:50pm	Novartis Gets FDA Approval for Kisqali to Treat Early Breast Cancer Patients	MT
06:56pm	FDA approves Novartis Kisqali(R) to reduce risk of recurrence in people with HR+/HER2- early breast cancer	DJ

Novartis receives FDA accelerated approval for Fabhalta(R) (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

August 07, 2024 at 05:30 pm

(MORE TO FOLLOW) Dow Jones Newswires

August 07, 2024 19:30 ET (23:30 GMT)

Latest news about Novartis AG

Novartis Gets FDA Approval for Kisqali to Treat Early Breast Cancer Patients	01:50pm	MT
FDA approves Novartis Kisqali(R) to reduce risk of recurrence in people with HR+/HER2- early breast cancer	12:56pm	DJ
Liquidia Says United Therapeutics' Interference Found by US Court to Have Caused Losses of Over $137 Million	09-16	MT
Kyverna Therapeutics, Inc. Announces CEO Changes	09-16	CI
Novartis' Breast Cancer Combo Drug Lowers Recurrence Risk in Late-stage Trial	09-16	MT
Novartis: results of breast cancer analysis	09-16	CF
Novartis' Kisqali Reduces Breast Cancer Recurrence by Nearly One-Third, Trials Show	09-16	DJ
Novartis Kisqali(R) shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer	09-16	DJ
NOVARTIS AG : Gets a Buy rating from UBS	09-11	ZD
EXECUTIVE CHANGES: Invinity replaces CEO; Gulf Keystone chair dies	09-06	AN
Veeva Systems: leader in cloud solutions for the life sciences industry	09-06
NOVARTIS : Goldman Sachs no longer Buy	09-05	CF
Such a long wait	09-05
Goldman Sachs Downgrades Novartis to Neutral From Buy, Adjusts Price Target to $121 From $119	09-05	MT
Novartis shares fall back as Morgan Stanley takes a break	09-05	CF
Voyager Therapeutics Gets Capsid License for Gene Therapy Program From Novartis	09-05	MT
Goldman Sachs Downgrades Novartis to Neutral, Trims PT	09-05	MT
EDX Medical Group Names New Chief Commercial Officer	09-05	MT
NOVARTIS AG : Goldman Sachs is Neutral	09-05	ZD
Novartis Starts Construction of New Radioligand Therapy Sites in US	09-04	MT
Novartis: two new radioligand units in the USA	09-04	CF
NOVARTIS : Jefferies upgrades to 'hold', share price consolidates	09-03	CF
Jefferies Downgrades Novartis to Hold, Lowers PT	09-03	MT
Jefferies Downgrades Novartis to Hold From Buy	09-03	MT
US will still pay at least twice as much after negotiating drug prices	09-03	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

2024-09-17 - Bank of America Global Healthcare Conference

More about the company